Adhesion of Escherichia coli in urinary tract infection.
In individuals prone to urinary tract infections the intestine is colonized by E. Coli strains that possess a combination of properties determining virulence. Such an E. coli strain may colonize the vaginal and periurethral area and ascend the urinary tract. The ability to attach to the mucosal surface is thought to be essential for E. coli to colonize and to remain in the urinary tract. Most E. coli from patients with urinary tract infection show one or both of two adherence properties. One may depend on the recognition by type 1 fimbriae of mannose-containing residues in the urinary slime. It is measured as mannose-sensitive haemagglutination and is found on most E. coli strains. The second adherence property is detected as attachment to human urinary tract epithelial cells and as mannose-resistant agglutination of human erythrocytes. This may depend on the recognition of globo-series glycolipids in the epithelial cell surface. Possession of this adherence factor is strongly related to virulence. Most strains from patients with acute pyelonephritis and cystitis have this property but it is rare in strains from patients with asymptomatic bacteriuria and strains from normal faeces. Local antibodies may interfere with bacterial attachment, thus possibly preventing the colonization that precedes urinary tract infection or modifying an established infection. Vaginal antibodies are known to coat E. coli from the stools. Antibodies in the urine of patients with acute pyelonephritis inhibit attachment of the infecting strain to uroepithelial cells. Antibodies directed against several bacterial surface structures, for example O antigen and fimbriae, are likely to inhibit attachment by steric hindrance or agglutination. The role of antibodies in adhesion-mediating structure such as fimbriae in susceptibility to and the outcome of human urinary tract infection remains to be investigated.
D000268:Adhesiveness; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000907:Antibodies, Bacterial / Q000276:immunology; D004848:Epithelium / Q000382:microbiology; D004926:Escherichia coli / Q000472:pathogenicity / Q000502:physiology*; D004927:Escherichia coli Infections / Q000382:microbiology*; D005260:Female; D010861:Fimbriae, Bacterial / Q000502:physiology; D006017:Glycolipids / Q000502:physiology; D006384:Hemagglutination; D006801:Humans; D008297:Male; D008358:Mannose / Q000494:pharmacology; D011513:Proteus mirabilis / Q000502:physiology; D014551:Urinary Tract / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D006017:Glycolipids; D008358:Mannose